• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Omnicell Inc.

    6/18/25 4:04:58 PM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    S-8 1 forms-82025x06.htm S-8 Document


    As filed with the Securities and Exchange Commission on June 18, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________________________________________________________________
    FORM S-8
    REGISTRATION STATEMENT UNDER
    THE SECURITIES ACT OF 1933
    OMNICELL, INC.
    (Exact name of registrant as specified in its charter)
    Delaware
    (State or other jurisdiction of incorporation or organization)
    94-3166458
    (I.R.S. Employer Identification No.)
    4220 North Freeway
    Fort Worth, TX 76137
    (Address of principal executive offices, including zip code)
    Omnicell, Inc. 2009 Equity Incentive Plan, as amended
    (Full title of the plans)
    Randall A. Lipps
    Chief Executive Officer, President and Chairman of the Board
    4220 North Freeway
    Fort Worth, TX 76137
    (877) 415-9990
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    ____________________________________________________________________________
    Copies to:
    Jessica S. Lochmann
    Foley & Lardner LLP
    777 East Wisconsin Avenue
    Milwaukee, Wisconsin 53202-5304
    (414) 271-2400
    ____________________________________________________________________________
        Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
    Large accelerated filer ☒
    Accelerated filer ☐
    Non-accelerated filer ☐

    Smaller reporting company ☐
    Emerging growth company ☐
        If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐




    EXPLANATORY NOTE
    Omnicell, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering 1,750,000 shares of the Registrant’s common stock (the “Common Stock”) issuable to eligible persons under the Omnicell, Inc. 2009 Equity Incentive Plan, as amended (the “2009 Plan”), which Common Stock is in addition to the shares of Common Stock previously registered on the Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on May 29, 2009 (File No. 333-159562), August 8, 2011 (File No. 333-176146), August 30, 2013 (File No. 333-190930), July 2, 2015 (File No. 333-205465), May 24, 2018 (File No. 333-225179), May 22, 2019 (File No. 333-231669), June 10, 2021 (File No. 333-256979), June 22, 2022 (File No. 333-265767), May 26, 2023 (File No. 333-272242), and June 21, 2024 (File No. 333-280384) (collectively, the “Prior Registration Statements”).
    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E of Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2009 Plan, are incorporated by reference into this Registration Statement and made part of this Registration Statement, except as amended hereby.
    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    The document or documents containing the information specified in Part I of this Registration Statement are not required to be filed with the Commission as part of this Registration Statement on Form S-8 and will be sent or given to the participants in the 2009 Plan as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
    1.    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025 (the “2024 Form 10-K”);
    2.    The information specifically incorporated by reference into the 2024 Form 10-K from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 3, 2025;
    3.    The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on May 7, 2025;
    4.    The Registrant’s Current Reports on Form 8-K, filed with the Commission on March 4, 2025, March 12, 2025 (excluding Item 7.01 and the related exhibits furnished therewith), May 23, 2025, and June 5, 2025;
    5.    All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the 2024 Form 10-K;
    6.    The description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A filed with the Commission on August 3, 2001, as updated by the Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Exchange Act filed as Exhibit 4.7 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, including any amendments or reports filed for the purpose of updating such description; and
    7.    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be
    2


    incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
    3


    ITEM 8. EXHIBITS
    Incorporated By Reference
    Exhibit Number
    Exhibit Description
    Form
    File No.
    Exhibit
    Filing Date
    4.1
    Amended and Restated Certificate of Incorporation of Omnicell, Inc.
    10-Q
    000-33043
    3.1
    9/20/2001
    4.2
    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Omnicell, Inc.
    10-Q
    000-33043
    3.2
    8/9/2010
    4.3
    Certificate of Designation of Series A Junior Participating Preferred Stock
    10-K
    000-33043
    3.2
    3/28/2003
    4.4
    Third Amended and Restated Bylaws of Omnicell, Inc.
    8-K
    000-33043
    3.1
    10/21/2022
    4.5
    Form of Common Stock Certificate
    S-1/A
    333-57024
    4.1
    7/24/2001
    5.1+
    Opinion of Foley & Lardner LLP as to the legality of securities being registered
    23.1+
    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
    23.2+
    Consent of Foley & Lardner LLP (included in Exhibit 5.1 to this Registration Statement)
    24.1+
    Power of Attorney (included on the signature page of this Registration Statement)
    99.1*+
    Omnicell, Inc. 2009 Equity Incentive Plan, as amended
    107.1+
    Calculation of Filing Fee Table
    _________________________________________________
    *    Indicates a management contract, compensation plan, or arrangement.
    +    Filed herewith.
    4


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fort Worth, State of Texas, on this 18th day of June, 2025.

    OMNICELL, INC.
    By:/s/ Nchacha E. Etta
    Nchacha E. Etta,
    Executive Vice President & Chief Financial Officer
    (Principal Financial Officer)
    5


    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Randall A. Lipps and Nchacha E. Etta, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the “Commission”), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the Registrant to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
    Signature
    Title
    Date
    /s/ RANDALL A. LIPPS
    Chief Executive Officer, President and Chairman of the Board
    (Principal Executive Officer)
    June 18, 2025
    Randall A. Lipps
    /s/ NCHACHA E. ETTA
    Executive Vice President & Chief Financial Officer
    (Principal Financial Officer)
    June 18, 2025
    Nchacha E. Etta
    /s/ BRIAN H. NUTT
    Vice President, Chief Accounting Officer and Corporate Controller
    (Principal Accounting Officer)
    June 18, 2025
    Brian H. Nutt
    /s/ JOANNE B. BAUER
    Director
    June 18, 2025
    Joanne B. Bauer
    /s/ EDWARD P. BOUSA
    Director
    June 18, 2025
    Edward P. Bousa
    /s/ MARY A. GARRETT
    Director
    June 18, 2025
    Mary A. Garrett
    /s/ KAUSHIK GHOSHALDirectorJune 18, 2025
    Kaushik Ghoshal
    /s/ MARK W. PARRISH
    Director
    June 18, 2025
    Mark W. Parrish
    /s/ BRUCE E. SCOTT
    Director
    June 18, 2025
    Bruce E. Scott
    /s/ ROBIN G. SEIM
    Director
    June 18, 2025
    Robin G. Seim
    /s/ EILEEN J. VOYNICK
    Director
    June 18, 2025
    Eileen J. Voynick

    6
    Get the next $OMCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $OMCL
    SEC Filings

    See more
    • SEC Form S-8 filed by Omnicell Inc.

      S-8 - OMNICELL, INC. (0000926326) (Filer)

      6/18/25 4:04:58 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      6/5/25 5:13:20 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      5/23/25 4:34:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Leadership Updates

    Live Leadership Updates

    See more
    • Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

      The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

      9/25/24 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

      FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me

      4/22/24 4:05:00 PM ET
      $CLOV
      $OMCL
      Medical Specialities
      Health Care
      Computer Manufacturing
      Technology
    • Omnicell Elects Eileen Voynick to Board of Directors

      Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e

      1/11/24 4:00:00 PM ET
      $MDRX
      $OMCL
      $CDK
      EDP Services
      Technology
      Computer Manufacturing
      Retail: Computer Software & Peripheral Equipment

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 1,146 shares, decreasing direct ownership by 0.28% to 403,523 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/17/25 5:27:57 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 332 shares, decreasing direct ownership by 0.28% to 117,126 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/17/25 5:27:11 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Director Parrish Mark W was granted 6,828 shares, increasing direct ownership by 12% to 65,255 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/3/25 4:12:37 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Financials

    Live finance-specific insights

    See more
    • Omnicell Announces First Quarter 2025 Results

      Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. "We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous P

      5/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the first quarter 2025, before market open on Tuesday, May 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 7437144. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About O

      4/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

      Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. "We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year," stated Randall Lipps, ch

      2/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omnicell upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00

      5/14/25 8:50:33 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by BofA Securities with a new price target

      BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously

      10/31/24 7:49:39 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell upgraded by Barclays with a new price target

      Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously

      8/2/24 7:36:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

      Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced updates to its second quarter and full year 2025 outlook for Non-GAAP EBITDA and Non-GAAP earnings per share, and the authorization of a new $75 million stock repurchase program. "The Administration's recent announcement of a reduction in tariff rates on imports from China has compelled us to update our second quarter and full-year 2025 outlook to reflect the expected diminished impact on our supply chain and anticipated improved profitability," stated Randall Lipps, chairman, president, chief executive officer,

      5/22/25 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces New Products for Perioperative and Clinic Settings

      RFID-Enabled Dispensing and Intelligent Inventory Management Software Aim to Unlock Greater Inventory Accuracy and Streamline Medication Management in Operating Rooms and Outpatient Clinics Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced new products designed to streamline workflows and enhance inventory visibility and management in perioperative and clinic settings. These products, which leverage RFID tracking and intelligent software workflows, expand Omnicell's connected platform that is intended to automate medication management processes and deliver intelligent insights to drive clinical

      5/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Opens New Innovation Lab in Austin, Texas

      Company Establishes New Hub Dedicated to Addressing Challenges Across the Medication Journey Omnicell, Inc. (NASDAQ:OMCL), ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced the opening of its Innovation Lab, located at 1005 East St. Elmo Road in Austin, Texas. The facility will serve as a hub focused on addressing challenges along the medication and supply journey and developing new technologies that are designed to solve evolving challenges faced by the healthcare industry. As hospitals and health systems are grappling with rising costs and staffing shortages, we believe that innovative automated technologies will be imp

      5/14/25 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:13:27 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      12/11/23 9:36:42 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      9/11/23 1:33:44 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      2/9/23 11:27:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology